Nippon Shinyaku Sets Up Promotion Agreement With Pfizer For Tramal In Japan
This article was originally published in PharmAsia News
Executive Summary
Nippon Shinyaku and Pfizer signed a license agreement allowing Pfizer to begin Japan promotion of the cancer and chronic pain drug Tramal (tramadol) sold by Nippon Shinyaku and the tramadol sustained formulation NS-24, which has been in Phase III trials since April 2012.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.